Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials
Vibeke Strand, Hendrik Schulze-Koops, Samar Al-Emadi, Cassandra D Kinch, David Gruben, Rebecca Germino, Carol A Connell, Eduardo Mysler · 2025
Read Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials by Vibeke Strand, Hendrik Schulze-Koops, Samar Al-Emadi, Cassandra D Kinch, David Gruben, Rebecca Germino, Carol A Connell, Eduardo Mysler (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12746493.txt.
Description
Vibeke Strand and co-authors re-cut arthritis drug trials by sex to see if a pill works alike in women and men, in a study from two thousand twenty-five. Over two thousand patients from three trials plus long extensions fed the re-check. Most patients were women, as in the disease at large.
The drug beat dummy pills in both sexes on joint scores. Men edged ahead on the strictest joint marks and some self reports. Daily function scores did not split by sex. Age curves did not explain the gaps. Safety and staying on the drug matched across sexes. Readers get a mostly even ledger with a male tilt at the top end.
Catalog record
| CREATOR | Vibeke Strand, Hendrik Schulze-Koops, Samar Al-Emadi, Cassandra D Kinch, David Gruben, Rebecca Germino, Carol A Connell, Eduardo Mysler |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |